Meta analysis on advanced NSCLC with EGFR mutations treated randomly by EGFR inhibitors

doi:10.3969/j.issn.1673-8640.2013.06.013

Abstract

Abstract: Objective　To use Meta analysis to evaluate the efficacy of epidermal growth factor receptor（EGFR）- tyrosine kinase inhibitors（TKIs）as first-line treatment for advanced non-small cell lung cancer（NSCLC）with EGFR mutations. Methods　Relevant literatures were searched through PubMed and Embase databases from January 2004 to April 2012. The implement standards for literature-selection were used to ensure the homogeneity of research. Two reviewers evaluated independently the quality of the included studies and extracted the data. Meta analysis was performed by RevMan 5.1 software. Risk ratio（RR）as efficacy index was chosen by overall response rate（ORR），and hazard ratios（HR）were calculated by progression-free survival（PFS）and overall survival（OS）times. The 95% confidence interval（CI）was calculated simultaneously. Results　Six phase Ⅲrandomly controlled trials were included for a total of 1 030 patients with NSCLS. This Meta analysis showed a statistical significance in ORR（RR＝2.19，95% CI＝1.68-2.15，P＜0.000 01）and PFS（HR＝0.43，95%CI＝0.35-0.52，P＜0.000 01）for patients who received EGFR-TKIs compared with patients who received chemotherapy. No statistical significance was observed in OS（HR＝0.98，95%CI＝0.81-1.18，P＝0.80）. Conclusions　EGFR-TKIs are effective as first-line treatment for advanced NSCLC. The EGFR mutation testing should be made for advanced NSCLC patients to predict efficacy to first-line therapy with EGFR-TKIs.

Key words: Epidermal growth factor receptor, Mutation, Non-small cell lung cancer, Tyrosine kinase inhibitor, Meta analysis

ZHANG Rong，CHEN Weiya，GAN Jiemin，ZHAO Hu，GU Zhaoxiang.. Meta analysis on advanced NSCLC with EGFR mutations treated randomly by EGFR inhibitors[J]. , 2013, 28(6): 506-510.

References

[1]Paez JG，Jänne PA，Lee JC，et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy [J]. Science，2004，304（5676）: 1497-1500.
[2]Lynch TJ，Bell D W，Sordella R，et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J]. N Engl J Med，2004，350（21）: 2129-2139.
[3]吴一龙，孙燕，廖美琳，等. EGFR突变型肺癌的处理[J]. 循证医学，2011，11（2）:65-68.
[4]Tierney JF，Stewart LA，Ghersi D，et al. Practical methods for incorporating summary time-to-event data into meta-analysis[J]. Trials，2007，8:16.
[5]Mok TS，Wu YL，Thongprasert S，et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med，2009，361（10）:947-957.
[6]Fukuoka M，Wu YL，Thongprasert S，et al. Bio-marker analyses and final overall survival results from a phase Ⅲ，randomized，open-label，first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in asia（IPASS）[J]. J Clin Oncol，2011，29（21）:2866-2874.
[7]Lee JS，Park K，Kim SW，et al. A randomized phase Ⅲ study of gefitinib versus standard chemotherapy（gemcitabine plus cisplatin）as a fi rst-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung [J]. J Thorac Oncol，2009，4（suppl）: abstr PRS.4.
[8]Mitsudomi T，Morita S，Yatabe Y，et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor（WJTOG3405）: an open label，randomised phase 3 trial [J]. Lancet Oncol，2010，11（2）:121-128.
[9]Maemondo M，Inoue A，Kobayashi K，et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J]. N Engl J Med，2010，362（25）:2380-2388.
[10]Zhou C，Wu YL，Chen G，et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer（OPTIMAL，CTONG-0802）: a multicentre，open-label，randomised，phase 3 study[J]. Lancet Oncol，2011，12（8）:735-742.
[11]Rosell R，Carcereny E，Gervais R，et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer（EURTAC）: a multicentre，open-label，randomised phase 3 trial[J]. Lancet Oncol，2012，13（3）: 239-246.
[12]Douillard JY，Shepherd FA，Hirsh V，et al. Mole-cular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase Ⅲ INTEREST trial[J]. J Clin Oncol，2010，28（5）:744-752.
[13]Maruyama R，Nishiwaki Y，Tamura T，et al. Phase Ⅲ study，V-15-32，of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer[J]. J Clin Oncol，2008，26（26）:4244-4252.
[14]Kim ES，Hirsh V，Mok T，et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer（INTEREST）: a randomised phase Ⅲ trial [J]. Lancet，2008，372（9652）:1809-1818.
[15]Zhu CQ，da Cunha Santos G，Ding K，et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 [J]. J Clin Oncol，2008，26（26）: 4268-4275.
[16]Bell DW，Lynch TJ，Haserlat SM，et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials[J]. J Clin Oncol，2005，23（31）:8081-8092.
[17]Giaccone G，Herbst RS，Manegold C，et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial--INTACT 1[J]. J Clin Oncol，2004，22（5）:777-784.
[18]Herbst RS，Giaccone G，Schiller JH，et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial--INTACT 2[J]. J Clin Oncol，2004，22（5）: 785-794.
[19]Gatzemeier U，Pluzanska A，Szczesna A，et al. Phase Ⅲ study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial[J]. J Clin Oncol，2007，25（12）:1545-1552.
[20]Cappuzzo F，Ciuleanu T，Stelmakh L，et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre，randomised，placebo-controlled phase 3 study[J]. Lancet Oncol，2010，11（6）: 521-529.
[21]Thatcher N，Chang A，Parikh P，et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised，placebo-controlled，multicentre study（Iressa Survival Evaluation in Lung Cancer）[J]. Lancet，2005，366（9496）:1527-1537.
[22]Hirsch FR，Varella-Garcia M，Bunn PA Jr，et al. Molecular predictors of outcome with gefitinib in a phase Ⅲ placebo-controlled study in advanced non-small-cell lung cancer [J]. J Clin Oncol，2006，24（31）:5034-5042.
[23]麦劲壮，李河，方积乾，等.Meta分析中失安全系数的估计[J].循环医学，2006，6（5）：297-300.
[24]Thongprasert S，Duffield E，Saijo N，et al. Health-related quality-of-life in a randomized phase Ⅲ first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC（IPASS）[J] . J Thorac Oncol，2011，6（11）:1872-1880.
[25]高云，陈嘉昌，朱振宇，等. EGFR基因突变及其检测方法的研究进展[J]. 分子诊断与治疗杂志，2011，14（1）:51-57.
[26]Keedy VL，Temin S，Somerfield MR，et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor（EGFR）mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy [J]. J Clin Oncol，2011，29（15）:2121-2127.